IDO1 and neoplasm: Thus, immunotherapies inducing extensive inflammation at the tumor site might benefit from a combination with an IDO1 inhibitor medication, as exposing a tumor to immune recognition is of little utility if the immune system cannot effectively eliminate it (12, 16, 57).